放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效分析  

Analysis of clinical effect by chemoradiotherapy combined with metastatic encephaloma radiotherapy in the treatment of non-small cell lung cancer with brain metastases

作　　者：高绍英[1] 李鹏龙[1] 吕建辉[2] 

机构地区：[1]山东省烟台市莱阳中心医院肿瘤一区,265200 [2]山东省烟台市莱阳中心医院放疗科,265200

出　　处：《中国实用医药》2016年第33期134-135,共2页China Practical Medicine

摘　　要：目的探讨放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效。方法选取43例非小细胞肺癌脑转移的患者作为研究对象,给予患者放化疗联合脑转移瘤放疗治疗,观察患者的生存情况及临床治疗效果。结果 43例患者经过相应的临床治疗后,1年存活率为69.8%(30/43),2年存活率为46.5%(20/43),3年存活率为25.6%(11/43)。结论采用放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效显著,值得临床推广使用。Objective To investigate clinical effect by chemoradiotherapy combined with metastatic encephaloma radiotherapy in the treatment of non-small cell lung cancer with brain metastases. Methods A total of 43 non-small cell lung cancer with brain metastases patients as study subjects all received chemoradiotherapy combined with metastatic encephaloma radiotherapy. Observation was made on survival situation and clinical effect in patients. Results After clinical treatment in 43 patients, they had 1-year survival rate as 69.8%（30/43）, 2-year survival rate as 46.5%（20/43）and 3-year survival rate as 25.6%（11/43）. Conclusion Implement of chemoradiotherapy combined with metastatic encephaloma radiotherapy shows excellent clinical effect in treating non-small cell lung cancer with brain metastases, and this method is worth clinical promotion and application.

关 键 词：放化疗 脑转移瘤放疗治疗 非小细胞肺癌 脑转移 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]